A novel coronavirus disease, COVID-19, has emerged as a global public health issue. Clinical course of disease significantly correlates with the occurrence of some comorbidities, among them type 2 diabetes. According to recent structural studies the dipeptidyl peptidase 4, a key molecule in the pathophysiology of diabetes, may influence the course of COVID-19. Since DPP4 inhibitors, gliptins, are widely used in diabetes patients, the exact role of DPP4 modulation in SARS-CoV-2 infection, at least in that group, urgently needs to be clarified. In this short review, we discuss this issue with more detail.

中文翻译：

---

DPP4 抑制剂和 COVID-19——圣杯还是另一个死胡同？

一种新型冠状病毒疾病 COVID-19 已成为全球公共卫生问题。疾病的临床病程与某些合并症的发生显着相关，其中包括 2 型糖尿病。根据最近的结构研究，糖尿病病理生理学中的关键分子二肽基肽酶 4 可能会影响 COVID-19 的病程。由于 DPP4 抑制剂 gliptins 广泛用于糖尿病患者，因此迫切需要阐明 DPP4 调节在 SARS-CoV-2 感染中的确切作用，至少在该组中。在这篇简短的评论中，我们更详细地讨论了这个问题。